Oncolytics aligns with FDA on pivotal pelareorep anal cancer trial design

• Oncolytics Biotech aligned with FDA on design of a pivotal trial for pelareorep in unresectable metastatic squamous cell carcinoma of anal canal.
• Study will use a randomized controlled design intended to support accelerated approval and full approval from a single trial.
• Plan targets patients whose disease progressed after standard first-line therapy, a setting with no FDA-approved treatment options.
• Prior study results in second-line or later disease were already presented, showing signs of more durable responses and improved survival versus current standard of care.
• Company expects to incorporate FDA feedback into final protocol for the pivotal study.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Oncolytics Biotech Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202604270810PRIMZONEFULLFEED9707128) on April 27, 2026, and is solely responsible for the information contained therein.